Hypophosphatemia in patients with chronic HBV

Giovanni Vitale, Pietro Andreone

DOI: https://doi.org/10.7175/rhc.v5i1S.928

Abstract

Phosphorus is an essential element for correct functioning of the organism. Alteration of serum phosphorus may be due to reduced dietary intake, altered by intra-extracellular, by excretion or reabsorption from the intestine, bone and kidney. In patients with chronic hepatitis B, hypophosphatemia may be secondary to several causes among which the most frequent are related to the use of drugs and the deficiency of vitamin D. Tenofovir is a first choice drug for the treatment of chronic hepatitis B and it can be used in patients with mild renal impairment. In fact renal failure induced by TDF is not frequent, dose-dependent and usually reversible. However, it’s recommended to avoid use other nephrotoxic drugs during treatment with TDF; monitor kidney function and phosphorus metabolism before and during therapy; adjust the doses of the drugs to the degree of renal failure; verify the presence of proximal tubulopathy through the calculation of the EFPi and the TMPi/GFR and consider the suspension of the TDF in the case of severe hypophosphoremia (< 1 mg / dl) or creatinine clearance < 50 ml/min). The aim of this review is to facilitate the recognition of druginduced hypophosphatemia and differentiate it from that due to other causes, in order to avoid unnecessary discontinuation of antiviral therapy.

Keywords

Hypophosphatemia; Chronic HBV; Nucleotide analogs

Full Text

HTML PDF

References

  • Bagnis CI, Karie S, Deray G, et al. Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Therapy 2009; 14: 481-8
  • Stokes C, Volmer D, Grünhage F. Vitamin D in chronic liver disease. Liver Int 2013: 33: 338-52; http://dx.doi.org/10.1111/liv.12106
  • Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-57; http://dx.doi.org/10.1038/ki.2008.130
  • Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM 2010; 103: 449-59; http://dx.doi.org/10.1093/qjmed/hcq039
  • Forster IC, Hernando N, Biber J, et al. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 2006; 70: 1548-59; http://dx.doi.org/10.1038/sj.ki.5001813
  • Donhowe JM, Freier EF, Wong ET, et al. Factitious hypophosphatemia related to mannitol therapy. Cli Chem 1981; 27: 1765-69
  • Liu PY, Jeng CY. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J Chin Med Assoc 2004; 67: 355-9
  • Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphatemia after voluntary hyperventilation. Clin Sci 2000; 98: 619-25; http://dx.doi.org/10.1042/CS19990172
  • Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005; 20: 155-9; http://dx.doi.org/10.1177/0885066605275326
  • Nowack R, Wachtler P. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. Clin Lab 2006; 52: 583-7
  • Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2: 136-48; http://dx.doi.org/10.1038/ncpneph0124
  • Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus depletion syndrome in man. N Engl J Med 1968; 278: 409-15; http://dx.doi.org/10.1056/NEJM196802222780802
  • Chines A, Pacifici R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int 1990; 47: 291-5; http://dx.doi.org/10.1007/BF02555911
  • Buell JF, Berger AC, Plotkin JS, et al. The clinical implications of hypophosphatemia following major hepatic resection or cryosurgery. Arch Surg 1998; 133: 757-61; http://dx.doi.org/10.1001/archsurg.133.7.757
  • Adami S, Romagnoli E, Carnevale V. Guidelines on prevention and treatment of vitamin D deficiency. Reumatismo 2011; 63: 129-47; http://dx.doi.org/10.4081/reumatismo.2011.129
  • Jacques J, Essig M, Carrier P. Is HBV-related renal tubulopathy before any antiviral treatment a reality? J Hepatology 2013; 58S: 229-30
  • Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab 2009; 27: 635-42; http://dx.doi.org/10.1007/s00774-009-0119-x
  • Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975; 56: 45-50
  • Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81; http://dx.doi.org/10.1056/NEJMra070553
  • Pfister MF,Forgo J, Ziegler U, et al. cAMP-dependent and -independent down regulation of type II Na-Pi cotransporters by PTH. Am J Physiol 1999; 276: F720-5
  • Assadi F. Hypophosphatemia an evidence-based Problem-Solving Approach to Clinical Cases. Iranian Journal of Kidney Diseases 2010; 4: 195-201
  • Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple. Nephrol Dial Transplant 2012; 27: 4273-87; http://dx.doi.org/10.1093/ndt/gfs493
  • Izzedine H, Launay-Vacher V, Isnard-Bagnis C. Drug-Induced Fanconi’s Syndrome. Am J Kidney Dis 2003; 41: 292-309; http://dx.doi.org/10.1053/ajkd.2003.50037
  • Mir O, Coriat R, Boudou-Rouquette P, et al. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012; 23: 280-1; http://dx.doi.org/10.1093/annonc/mdr525
  • Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987; 80: 1147-54; http://dx.doi.org/10.1172/JCI113172
  • Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 1998; 35: 201-6; http://dx.doi.org/10.1177/000456329803500203
  • Walton RJ, Bjivoet OLM. Nomogram for derivation of renal threshold of phosphate concentration. Lancet 1975; 2: 309-10
  • Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39: 35-46; http://dx.doi.org/10.1111/apt.12538
  • Frascà GM, Balestra E, Tavio M, et al. Il danno renale da farmaci antivirali. G Ital Nefrol 2012; 29: 109-14
  • Fontana RJ. Side Effects of Long-Term Oral Antiviral Therapy for Hepatitis B. Hepatology 2009; 49: S185-95; http://dx.doi.org/10.1002/hep.22885
  • Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22: 99-103; http://dx.doi.org/10.1089/apc.2007.0052
  • Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-8; http://dx.doi.org/10.1097/01.qai.0000243103.03265.2b
  • Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15: 1695-700; http://dx.doi.org/10.1097/00002030-200109070-00013
  • Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282: 2305-12; http://dx.doi.org/10.1001/jama.282.24.2305
  • Izzedine H, Hulot JS, Launay-Vacher V. Renal safety of adefovir dipivoxil in patients with chronich epatitis B: two double-blind, randomized, placebo-controlled studies. Kidney International 2004; 66: 1153-8; http://dx.doi.org/10.1111/j.1523-1755.2004.00866.x
  • European Association for the Study of The Liver. EASL Clinical Practice Guidelines: Management of chronich epatitis B virus infection. J Hepatology 2012; 57: 167-85; http://dx.doi.org/10.1016/j.jhep.2012.02.010
  • Viread: EPAR – Summary for the public. Disponibile su http://www.ema.europa.eu/
  • Hepsera: EPAR - Summary for the public. Disponibile su http://www.ema.europa.eu/
  • Marcellin P, Heathcote EJ, Buti M. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis. N Engl J Med 2008; 359: 2442-55; http://dx.doi.org/10.1056/NEJMoa0802878
  • Marcellin P, Gane E, Tsai N, et al. Seven years of treatment with tenofovir disoproxil fumarate for chronic Hepatitis B Virus infection is safe and well tolerated and associated with sustained virological, biochemical, and serological responses with no detectable resistance. Hepatology 2013; 58 (S1): 649A; http://dx.doi.org/10.1002/hep.26856
  • Hezode C, Causse X, Larrey D, et Al. Virological response and tolerance of Tenofovir DF (TDF) in the elderly is similar to younger patients in real life practice. J Hepatol 2013; Supp 1: 58
  • Fung S, Kwan P, Horban A, et al. Tenofovir DF (TDF) is safe and well tolerated in chronich epatitis B (CHB) patients with pre-existing mild renal impairment. J Hepatol 2013; 58: S301-2; http:// dx.doi.org/10.1016/S0168-8278(13)60746-1
  • Gish R G, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofoviror entecavir for chronichepatitis B. Clin Gastroenterol Hepatol 2012; 10: 941-6; http:// dx.doi.org/10.1016/j.cgh.2012.04.008
  • RCP Viread® – Informazioni e raccomandazioni sulla sicurezza renale. Disponibile su www. agenziafarmaco.gov.it/allegati/rcp_viread300408.pdf

Statistics

Abstract: 1918 views
HTML: 2182 views
PDF: 379 views

Refbacks

  • There are currently no refbacks.




© SEEd srl